Participants with clinical or radiographic evidence of pancreatitis are excluded
Patient MUST have had progressive disease (radiographic or clinical) while on arm 1 single agent nivolumab while registered to A091401
Patients with brain metastases are eligible if these lesions have been previously treated and the patients have no clinical or radiographic evidence of progression within 30 days prior to enrollment.
Participants with evidence for central nervous system (CNS) lymphoma on neurological exam and/or with radiographic evidence (if radiographic studies are done) of CNS lymphoma (inclusive of parenchymal, vitreal, or leptomeningeal involvement)
Documented radiographic or clinical disease progression on no more or less than one previous line of standard therapy
Has experienced documented objective radiographic or clinical disease progression during or after receiving more than 1 line of therapy.
Radiographic evidence of intratumor cavitation.
Patients on either treatment arm will considered for crossover if they demonstrate evidence of radiographic disease progression from the initial treatment
Radiographic evidence of persistent, progressive, or recurrent disease in an area previously treated with TACE and determined from 3 months or more (no upper time limit) after initial TACE; this evaluation should be within 6 weeks of date of study eligibility
Measurable disease of at least 1.5 cm as documented by radiographic technique
Subjects must have demonstrated either tumor progression or recurrence by any of the radiographic criteria and/or clinical criteria as defined below:\r\n* Subjects with progressive non-resectable disease regardless of location in the brain or spine are eligible for this study; patients with evidence of leptomeningeal dissemination are eligible for this study; patients do not require biopsy/histologic confirmation at the time of progression or relapse\r\n* Radiographic progression is defined as > 40% increase in the product of the three perpendicular diameters of current tumor relative to the baseline measurement (defined as either the initial scan or scan at start of a previous therapy): length (L) x width (W) x transverse (T) (current scan) > 1.4 x L x W x T (baseline scan), or the development of any new sites of disease independent of the response of the initial tumor\r\n* Post radiation changes are often seen on post-treatment imaging studies, so that classification of a patient as having progressive disease may require several serial magnetic resonance imaging (MRI)â€™s if the child has received radiation within the preceding 12 months\r\n* Tumor volume includes the entire tumor volume seen on gadolinium enhanced T1 magnetic resonance (MR) imaging plus non-enhancing abnormality seen on T2 or fluid attenuated inversion recovery (FLAIR); coronal and axial images will be evaluated\r\n* All tumor cysts will be included in the tumor volume\r\n* Clinical progression without radiographic progression includes children with optic pathway gliomas who demonstrate sustained decrease in visual fields and/or acuity in three serial vision examinations; each of the vision examinations must be performed > 2 weeks apart\r\n* Children with previously negative cerebrospinal fluid (CSF) cytology who show evidence of tumor cells in fluid obtained by lumbar puncture can be designated as having progressive disease in the absence of radiographic evidence of progression
NSCLC patients with radiographic evidence of major airway or blood vessel invasion by cancer, radiographic evidence of intra-tumor cavitation, or gross hemoptysis (>= one teaspoon) within the preceding 2 months.
Radiographic, biochemical, or clinical evidence of tumor progression over a period of up to 12 months in at least one site
Radiographic evidence of progression/recurrence of the measurable disease more than 12 weeks after the end of initial radiation therapy
No clinical or radiographic evidence of malignant regional adenopathy
Radiographic evidence of metastatic disease
Radiographic or clinical disease recurrence or progression during or after the last line of systemic therapy
Evidence of radiographic invasion into stomach, duodenum or peritoneum (if not certain confirmation must be obtained prior to enrolment)
Patients must have radiographic and/or CSF cytological evidence of LMD
Radiographic or clinically measurable evidence of disease progression
T1 with T ?1.5cm, T2 or T3 by at least one radiographic or clinical measurement
Progression of disease by radiographic imaging (10% increase in size by RECIST version [v]1.1 within 6 months of registration) or presence of new lesions
Radiographic evidence of metastatic disease
Radiographic disease recurrence or progression during or after the last line of chemotherapy
Have documented objective radiographic progression after stopping treatment with first-line therapy; Note: the same image acquisition and processing parameters should be used throughout the study for a given subject
Radiographic evidence of cavitary or necrotic tumors
Radiographic or cytologic evidence of leptomeningeal or multifocal disease at any time prior to study entry
PHASE II SCLC: Radiographic evidence of disease progression after initial therapy should have been documented
Radiographic imaging demonstrating uterine cancer that is probably stage I or II
Diagnosis of widespread visceral and/or osseous metastatic disease based on clinical and radiographic evidence; (patients may continue on study if surgery shows a non-malignant process)
Radiographic evidence of an intramedullary occlusion by blastic metastases that would necessitate an alternative method of treatment, such as a plate/screw construct
Patients with advanced hip arthritis on radiographic imaging
Participants with LL must have radiographic evidence of disease
Radiographic evidence of renal cancer with IVC tumor thrombus
Based on clinical and radiographic evidence the tumor needs to be deemed resectable preoperatively
ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Radiographic evidence of pancreatic cancer recurrence
Absence of radiographic evidence of extrathyroidal extension
Radiographic or cytologic evidence of leptomeningeal disease
Radiographic evidence of cavitary or necrotic tumors
Radiographic evidence of progression/recurrence of the measurable disease more than 12 weeks after the end of the initial radiation therapy
There is no limit as to the number or type of prior drug treatments but patients must have radiographic evidence of progressive disease
Radiographic images demonstrating the presence of mucinous peritoneal carcinomatosis (PMP)
Patients with untreated positive blood cultures or progressive infections as assessed by radiographic studies
Evidence of measurable or evaluable disease by clinical, radiographic, or laboratory assessment
cT1N0- tumour invasion into submucosa, no radiographic evidence of mesorectal nodal metastasis, tumour deposits or vascular invasion.
Patients must not have experienced radiographic disease progression or clinical signs of symptoms of instability requiring urgent intervention.
Radiographic demonstration of disease progression following prior therapy
Unequivocal radiographic evidence of tumor progression by MRI within 14 days prior to registration
Radiographic evidence of major blood vessel invasion/infiltration
In the case of malignant glioma patients, they must have previously undergone standard-of-care treatment including surgery, radiation, and first line adjuvant chemotherapy prior to the experimental treatment (WP1066); in the case of melanoma patients with brain metastasis, they may have previously undergone a resection (with radiographic evidence of progression), have undergone gamma knife radiosurgery (with radiographic evidence of progression), or have been treated with other systemic therapies that failed
Clinical or radiographic evidence of disease progression
Confirmation of radiographic stage as borderline resectable disease by real-time Alliance central radiographic review
Radiographic evidence of metastatic disease
Clinical, radiographic or pathologic evidence of multicentric disease
Documented disease refractory to at least one PD1/PD-L1 inhibitor, defined as disease progression following at least 2 infusions of the same drug; radiographic disease progression will be documented by the institutional radiologist based on any radiographic evidence (magnetic resonance imaging [MRI], computed tomography [CT], positron emission tomography [PET], or other modalities, etc.) of disease progression on two separate radiographic scans assessment obtained at least 4 weeks apart; this minimum 4-week interval is required to define PD-1 inhibitor resistance based on imaging; alternatively, clinical disease progression may be documented on examination by the treating investigator
Radiographic or cytologic evidence of diffuse leptomeningeal extension - tumors with limited subependymal involvement are eligible
No clinical or radiographic evidence of pancreatitis
Patients with T4 disease with radiographic evidence of massive invasion of a large pulmonary artery and tumor causing significant narrowing and destruction of that artery are excluded
At least one tumor that can be measured on a radiographic scan
Radiographic evidence of recurrent NSCLC prior to afatinib treatment
Prior or present evidence of distant metastatic disease as assessed by radiographic imaging;
Radiographic evidence of major blood vessel invasion/infiltration.
Radiographic demonstration of disease progression by MRI following prior therapy.
Documented progressive disease based on radiographic, clinical or pathologic assessment during or subsequent to last therapy.
All subjects must have histologic evidence of G4 MG (including glioblastoma and gliosarcoma) and radiographic evidence of recurrence or disease progression (defined as either a greater than 25% increase in the largest bidimensional product of enhancement, a new enhancing lesion, or significant increase in T2 FLAIR).
Experienced an investigator-determined confirmed cutaneous or radiographic disease progression after stopping their initial treatment with MK-3475
Radiographic evidence of cavitary or necrotic tumours or local invasion of major blood vessels by MPM
History of or current clinical, radiographic, or pathologic evidence of in-transit metastases, satellite, or microsatellite lesions
Radiographic progression on bevacizumab by Revised Assessment in Neuro-Oncology (RANO) criteria
Patients must have symptomatic or radiographic progression during or after treatment with a PD-(L)1 inhibitor administered either as monotherapy or in combination.
Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1
Have radiographic evidence of pulmonary intratumor cavitation, regardless of tumor histology.
No radiographic evidence of cavitary or necrotic tumors
Documented objective radiographic or clinical disease progression on two previous lines of standard therapy
Physical, clinical, radiographic or pathologic evidence of satellite, in-transit, regional, or distant metastatic melanoma.
Enrollment within 28 days of the date of radiographic diagnosis
Radiographic or clinical evidence of regional tumor nodal recurrence, including pathological pelvic lymph nodes >= 2 cm in short-axis diameter; radiographic evidence of distant metastases is also an exclusion
Radiographic evidence of major blood vessel invasion/infiltration.
Radiographic evidence of metastatic disease; evaluable non-target lesions and/or bone only metastasis are permitted
Participants must have radiographic evidence of metastatic prostate cancer
Measurable disease of at least 1.5 cm as documented by radiographic technique
Patients must have measurable disease, documented by clinical and radiographic criteria
Metastatic (stage IV) disease (including involvement of the colon, adrenals, or kidney, or radiographic evidence of peritoneal seeding or pulmonary metastases)
Clinical or radiographic evidence of central nervous system metastases or significant cardiovascular disease
Patients must have measurable radiographic disease; patients with previous complete resection are only eligible if there is measurable radiographic disease which is clearly felt to represent locally recurrent disease
If the subject received immunotherapy, the documented radiographic disease progression is required
There is radiographic evidence of leptomeningeal disease prior to study entry
Patients with radiographic or cytologic evidence of leptomeningeal or multicentric disease will be excluded and replaced if needed
Documented progressive disease based on radiographic, clinical or pathologic assessment during or subsequent to last therapy.
Evidence of any other primary cancers or metastases; evidence of deep soft-tissue or bony invasion, which would preclude transoral minimally invasive surgery (TMIS) by clinical and/or radiographic exam
Radiographic progression in soft tissue or bone by modified RECIST 1.1 for subjects with measurable disease; or
Documented progressive disease based on radiographic, clinical or pathologic assessment.
Radiographic evidence of cavitary or necrotic tumors
Documented progressive disease based on radiographic, clinical or pathologic assessment during or subsequent to last therapy.
Must have disease progression or recurrence documented by radiographic assessment following treatment after last chemotherapy or chemoradiation regimen (completed within the previous 12 months).
Clinical (e.g. multiple new cranial nerve deficits in the absence of obvious radiographic disease to explain symptoms) or radiographic evidence of leptomeningeal disease
After concomitant platinum-based CRT, no evidence of disease (NED) on clinical and radiographic examinations
The participant has radiographic evidence of intratumor cavitation, regardless of tumor histology
Radiographic evidence of disease
The complete set of baseline radiographic images must be available before treatment initiation.
Radiographic progression by RANO Working Group Criteria will be confirmed by Imaging Endpoints, a central imaging vendor.
Measurable disease in the breast or axilla that measures at least 1 cm by either clinical or radiographic measurement
Unequivocal radiographic evidence for tumor progression by MRI. It is understood that some patients may be resected prior to enrolling onto protocol
Presence of distant metastatic disease; patients will undergo radiographic evaluation to exclude the possibility of distant metastatic disease; for patients who have undergone pre- or postoperative biopsies that definitively diagnose ICC, the diagnostic studies may be modified at the discretion of the MSKCC principal investigator; clinical or radiographic evidence of metastatic disease to regional lymph nodes will be allowed, provided it is amenable to resection
Radiographic evidence of central nervous system metastases that are not well controlled with local therapy (irradiation or surgery)
Radiographic evidence of disease
Radiographic evidence of disease progression by RECIST criteria on or after the last anti-cancer therapy within the 6 months prior to randomization.
All patients must have histological evidence of a solid malignant tumor (hematological malignancies are excluded) with convincing clinical, radiographic or isotopic evidence of cancer, for which no effective proven treatment exists. CNS associated tumors are preferred, but not required. Patients must sign an informed consent that complies with the investigator/DEKK-TEC policies and approved by a Human Investigation Review Committee.
Patients must have evidence for tumor recurrence or progression by MRI as determined by radiographic review of images by an attending neuro-oncologist or neuro-radiologist at UCSF
Radiographic evidence of cavitary or necrotic tumors
Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of major blood vessels
The participant has experienced radiographic, biochemical, and/or scintigraphic disease progression while on a regimen that includes octreotide
Radiographic evidence measurable of residual or metastatic disease after surgery
Radiographic evidence of cavitary or necrotic tumor and local invasion of major blood vessels
Primary brain cancer (presumed gliomas with no radiographic or clinical evidence of metastatic disease to the brain)
Radiographic evidence of a biliary hilar stricture OR intrahepatic but no extrahepatic biliary ductal dilation.
Known radiographic evidence of a Bismuth-Corlette type 1 biliary stricture.
Clinical (e.g. multiple cranial nerve deficits in the absence of obvious radiographic disease to explain symptoms) or radiographic evidence of leptomeningeal disease
Willingness to undergo radiographic evaluation if screening findings are abnormal
Clinical or radiographic evidence of metastatic disease
Absence of metastatic disease as documented by radiographic scans
Clinical and/or radiographic evidence of residual or persistent breast cancer
Initiation of new therapy for recurrent and/or progressive metastatic disease since radiographic documentation of recurrence/progression.
Initiation of new therapy for progressive metastatic disease since radiographic documentation of progression
Participants with known clinical or radiographic evidence of metastatic CNS disease
Post treatment subjects will have radiographic abnormalities that may or may not be recurrent tumor
Radiographic evidence of metastatic disease
Known prosthetic devices that would prohibit imaging of lesion of interest due to radiographic artifact
Have measurable disease that is amenable to a radiographic or ultrasound-guided biopsy or may be biopsied in the office without radiologic guidance.
Patients must have unresectable or metastatic, histologically confirmed low or intermediate grade (Klimstra Criteria) pancreatic neuroendocrine tumor (PNET) with radiological evidence of disease progression since last treatment
Fungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 month
Radiological progression (confirmed at least 4 weeks after the initial scan showing PD); or
Patients with fungal pneumonia with radiological progression after receipt of amphotericin formulation or mold-active azoles for greater than 1 month will not be eligible for this protocol
Patient must have progressed on their most recent line of therapy. Progression must have been demonstrated by radiological or clinical assessment.
Radiological or objective evidence of recurrence or progression on or after the last systemic therapy prior to enrollment
Documented radiological evidence for disease progression (measurable or nonmeasurable) =< 12 months prior to enrollment
Radiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI, e.g., gefitinib or erlotinib. In addition, other lines of therapy may have been given. All patients must have documented radiological progression on the last treatment administered, prior to enrolling in the study.
Diagnosis of radiological progression while on or after first platinum-based systemic therapy
Has radiological documentation of disease progression while receiving continuous treatment with erlotinib, gefitinib, or afatinib.
Fungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 month
Patients must have radiological evidence of disease progression following the most recent treatment
Surgical or radiological treatment of lesions contraindicated
Inability to undergo contrast radiological assessments
Failure of at least one line of systemic anti-cancer therapy for advanced NSCLC defined as either of the following: \r\na) Radiological documentation of disease progression (or failure to achieve a response) or \r\nb) Discontinuation due to toxicity
The patient must have documented disease limited to the peritoneal surface, amenable to complete cytoreduction indicated by:\r\n* Disease confined to the peritoneal surfaces\r\n* No parenchymal liver metastases\r\n* No evidence of clinical, biochemical or radiological biliary obstruction\r\n* Small volume of disease in the gastro-hepatic ligament defined by a < 5 cm mass in the epigastric region on cross-sectional imaging\r\n* No clinical or radiological evidence of hematogenous or distant nodal metastasis
Patients with clinical or radiological evidence of bone (>= 3 sites, or predominantly lytic if < 3) or other extranodal metastasis
Patients with fungal infection and radiological progression after receipt of amphotericin B or active triazole for greater than 1 month
No clinical or radiological evidence of metastatic disease or local progression
Patients must have documented radiological disease progression either during or after the first-line therapy.
Radiological documentation of disease progression:
No evidence of metastatic disease by clinical and radiological staging
For the purpose of obtaining a RECIST v1.1 baseline scan, participants must have a\n             radiological evaluation conducted no more than 28 days prior to beginning study\n             therapy (PLD).  NOTE: For participants with a history of CNS metastasis, baseline\n             radiological imaging must include an evaluation of the head.
Radiological evidence of metastatic disease
Patients with fungal pneumonia with radiological progression after receipt of amphotericin formulation or mold-active azoles for greater than 1 month will not be eligible for this protocol (either regimen A or B)
Radiological evidence of CNS metastases
Fungal infections with radiological progression after receipt of amphotericin product or active triazole for > 1 month
Definitive clinical or radiological evidence of metastatic disease
Fungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 month
Radiological stage T1-T2 N0 Mx/M0 disease.
Radiological evidence of multifocal disease, tumors extending into or crossing the corpus callosum or leptomeningeal disease.
Radiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI. Additional other lines of therapy may have been given. All patients must have documented radiological progression on the last treatment administered prior to enrolling in the study.
Documented radiological disease progression during the most recent treatment regimen for metastatic disease
Radiological documentation of disease progression following 1st line EGFR TKI Treatment without any further treatment
Evidence of at least one measurable lesion as detected by radiological or photographic methods
Radiological evidence for progressive disease (measurable or non-measurable) within 12 months prior to registration; patients who have received anti-tumor therapy during the past 12 months (including octreotide analogs) must have had radiological documentation of progression of disease while on or after receiving therapy
Radiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI e.g. gefitinib or erlotinib (with the exception of 1st line expansion cohort). In addition other lines of therapy may have been given. All patients must have documented radiological progression on the last treatment administered prior to enrolling in the study.
Evidence of at least one measurable lesion as detected by radiological or photographic methods
Objective evidence of disease progression (clinical or radiological) during or after at least 1 (V600 Wildtype) or at least 2 (V600 mutation positive) prior treatment regimens
Patients with clinical, radiological/laboratory, or pathological evidence of distant metastatic disease
Fungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 month
Radiological suspicion of pseudoprogression or radionecrosis
Patients with fungal pneumonia with radiological progression after receipt of amphotericin formulation or mold-active azoles for greater than 1 month
Clinical or radiological evidence of metastatic disease
Has radiological documentation of disease progression while receiving continuous treatment with erlotinib, gefitinib, afatinib, or osimertinib
